In the competitive field of Cancer Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Cancer Drugs technology and learn how to protect your intellectual property.

Patent challenges are becoming increasingly common in the Cancer Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Cancer Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Cancer Drugs industry

EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 14, 2024BRAND MURRAY FULLER LLP
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 14, 2024BENDELE, TANJA DR.
EP3632907N-(Azaaryl)Cyclolactam-1-Carboxamide Derivative, Preparation Method Therefor, And Use ThereofABBISKO THERAPEUTICS CO., LTD.Nov 13, 2024DECIPHERA PHARMACEUTICALS, LLC
EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 13, 2024TEVA PHARMACEUTICAL INDUSTRIES, LTD.
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 13, 2024TEVA PHARMACEUTICAL INDUSTRIES LTD
EP3585402Compositions, Articles Of Manufacture And Methods Related To Dosing In Cell TherapyJUNO THERAPEUTICS, INC.Nov 12, 2024BOULT WADE TENNANT LLP
EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 11, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 11, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP3215166Altering Gene Expression In Cart Cells And Uses ThereofTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAOct 22, 2024MARGARET DIXON LIMITED
EP3596123Fc-Optimized Anti-Cd25 For Tumour Specific Cell DepletionTUSK THERAPEUTICS LTDOct 4, 2024PFIZER INC.

To stay ahead in the competitive Cancer Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Cancer Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2478907Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY, INC.22
EP2962690Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE CORPORATION15
EP2493466Mar 10, 2021Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA S.A.13
EP3725778Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS LLC11
EP3078667Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES11
EP3342411Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS INTERNATIONAL PHARMACEUTICAL AG10
EP3616720Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI & CO., LTD.10
EP3322731Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL-MYERS SQUIBB COMPANY9
EP3351246Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS AG9
EP2269603May 20, 2015Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTIS AG9